Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long-term extension results.

Dan TurnerJoel R RoshStanley A CohenAnne M GriffithsJeffrey S HyamsJarosław KierkuśOmoniyi J AdedokunRichard StraussLilianne KimSheri Volgernull null

Published in: Journal of pediatric gastroenterology and nutrition (2024)

Efficacy and pharmacokinetics through 1 year and safety and immunogenicity through 4 years of ustekinumab treatment in paediatric patients with CD were generally comparable to those previously reported in adults.

Keyphrases

intensive care unit
emergency department
replacement therapy